Pelago Bioscience AB has entered a method licensing agreement with GlaxoSmithKline.
The agreement regards the use of the Cellular Thermal Shift Assay for determination and quantification of drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license to the CETSA method for use in research & development.
Pelago Bioscience was spun out from the Karolinska Institute and was founded to provide and develop the patented Cellular Thermal Shift Assay. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development.
Advertisement
